Rare stumble for Keytruda in Phase III stomach cancer trial
Related Biotechnology, Pharmaceutical and Healthcare News
New Jersey, USA’s Merck & Co, has revealed its KEYNOTE-061 trial investigating Keytruda (pembrolizumab)…
Original Article: Rare stumble for Keytruda in Phase III stomach cancer trial
NEXT ARTICLE
More From BioPortfolio on "Rare stumble for Keytruda in Phase III stomach cancer trial"